Startups, BioPharma

Canaan, Vivo Capital, Frazier raising $21.3M for stealth infectious disease startup

The three West Coast venture firms are teaming up to build a stealth new startup called Nexcida Therapeutics. They are developing therapeutics for infectious disease, but haven't disclosed anything else.

Three West Coast healthcare venture capital firms – Canaan Partners, Vivo Capital and Frazier Healthcare – are teaming up to launch a stealth new startup called Nexcida Therapeutics. It’s focused on infectious disease therapeutics, CEO David Socks said in an email.

The startup was launched by Frazier Healthcare, which also led the Series A, with Vivo and Canaan investing as well. Socks is an alum from Cadence Pharmaceuticals and Incline Therapeutics, is the startup’s CEO.

It’s raised $2.75 million of a proposed $21.3 million round, according to a regulatory filing. Nexcida is in its nascence and under the radar – it has no website.

Canaan and Frazier Healthcare are your typical life sciences VCs; Vivo Capital, however, focuses on building companies both stateside and in China.

Photo: Flickr user Fun Flying

Shares0
Shares0